Dyreforsøg tyder på, at indgift af doxorubicinhydrochlorid i form af liposomer reducerer risikoen for ekstravasationsskader.
Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury.